RxDoctor Payments Data

Ashley Kirby, NP

Family · Pueblo, CONPI 1427235423

Payments from drug & device makers

$2,359in general payments, 2019–2025

Across 125 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$656
  • Novo Nordisk$292
  • AstraZeneca$291
  • Scilex Pharmaceuticals Inc.$125
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$118
  • Lilly USA, LLC$99
  • plus $778 from 20 others

What the payments were for

  • Food & beverage$2,347100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,359 in reported general payments places this provider in the 85th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$37,902
Medicare patients
68
Services billed
1,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide91$115,899
FarxigaDapagliflozin Propanediol91$96,039
OzempicSemaglutide55$56,496
Tresiba Flextouch U-200Insulin Degludec71$47,511
VraylarCariprazine Hcl30$44,729
Xtampza ErOxycodone Myristate95$38,194
TradjentaLinagliptin32$31,551
TrulicityDulaglutide22$26,256
EliquisApixaban20$17,133
MyrbetriqMirabegron16$15,203
LinzessLinaclotide14$15,119
XareltoRivaroxaban15$12,548
DapagliflozinDapagliflozin Propanediol12$9,244
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen256$9,028
SymbicortBudesonide/Formoterol Fumarate32$8,896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$99$142,155113 claims
AstraZenecaFarxiga, Symbicort$291$104,935123 claims
AbbVieVraylar, Linzess, Synthroid$656$60,50156 claims
Novo NordiskOzempic$292$56,49655 claims
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$78$44,352106 claims
Boehringer IngelheimTradjenta$21$31,55132 claims
PfizerEliquis$90$17,13320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,182 family providers in Colorado.

Other family in Pueblo

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →